Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Myasthenia Gravis Therapeutics Pipeline Analysis 2017 - Key Players are Alexion Pharmaceuticals, Inc., CSL Behring LLC, Novartis AG - Research and Markets

Research and Markets
Posted on: 13 Dec 17

The "Myasthenia Gravis Therapeutics Pipeline Analysis, 2017" report has been added to Research and Markets' offering.

The study analysed that the therapeutics pipeline comprises of approximately 19 drug candidates in different stages of development. Myasthenia gravis is a chronic autoimmune disorder that acts on neuromuscular junction and leads to the weakening of skeletal muscles. This causes loss of muscle control in moving the body parts, such as the movement of arms and legs, breathing, loss of eye movements, chewing, talking, and swallowing. The situation of the disease worsens after a period of activity and improves after a period of rest.

Various companies, educational institutes and medical organizations are collaborating for the development of drugs for the treatment of this disease. For instance, Merck & Co., Inc. entered into a multi-targeted collaboration and license agreement with Ra Pharmaceuticals, Inc. to use the latter's drug discovery technology platform for the development of orally available cyclic peptides for the treatment of myasthenia gravis.

It has been observed that most of the drugs in the myasthenia gravis therapeutics pipeline, are being developed from the natural source. NT-1654 is a heparan sulfate proteoglycan, and is under development by Neurotune AG for the treatment of myasthenia gravis. The drug acts as a neuromuscular junction stimulator.

Some of the key players developing drugs for the treatment of myasthenia gravis include Alexion Pharmaceuticals, Inc., CSL Behring LLC, Novartis AG and others.

Key Topics Covered:

1. Research Background

2. Research Methodology

3. Executive Summary

4. Pipeline Outlook

4.1. IPF Disease Overview

4.2. Key Drivers

4.3. Key Barriers

4.4. IdioPAThic Pulmonary Fibrosis Pipeline Analysis

4.5. Inactive Drug Candidates

4.6. Discontinued Drug Candidates

5. IPF Therapeutics Pipeline Analysis by Phase (2017)

5.1. Phase III: Drug Profiles

5.2. Phase II: Drug Profiles

5.3. Phase I: Drug Profiles

5.4. Pre-Clinical: Drug Profiles

5.5. Discovery: Drug Profiles

6. Clinical Trials Analysis

6.1. Clinical Trials Analysis, by Region

6.2. Clinical Trials Analysis, by Trial Status

7. Competitive Landscape

7.1. Key Players Benchmarking for IPF Therapeutics Pipeline

7.2. SWOT Analysis of IPF Therapeutics Pipeline

8. Company Profiles

8.1. Companies having Pipeline of IPF Therapeutics

9. Appendix

For more information about this report visit

View source version on

Business Wire

Last updated on: 13/12/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.